ClinicalTrials.gg
Not yet recruitingNCT05686629Updated Oct 24, 2023

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

A Phase 2 interventional study of Jaktinib hydrochloride tablets in Novel COVID-19-Infected Pneumonia, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-24.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 472 studies in COVID-19 with a site in China — 53 open to participants now, 75 under way, 8 of them phase 3. COVID-19 · China.

Planned enrollment
190th of 330
120 · median 200
Started
2024
with 12 others
Phase 2
48 of 472
4 open now
Primary completion
2025-02
later than 53 of 74 live
Registered
336th of 472
by date

Among the 472 studies in COVID-19 with a site in China, this one is the 190th largest by planned enrollment of the 330 interventional ones that give a count, is one of 13 that started in 2024, is one of 48 in phase 2, reaches primary completion later than 53 of the 74 other live ones, and was the 336th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

53 of the 472 studies in COVID-19 with a site in China are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 472 studies in COVID-19 with a site in China, or all of them as a file.
02

Study summary

This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 120 eligible patients with severe novel coronavirus pneumonia.

03

Conditions studied

  • Novel COVID-19-Infected Pneumonia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 80 years old (including threshold), regardless of gender;
  • There is a history of novel coronavirus antigen- or nucleic acid-positive infection within 1 week;
  • HRCT is consistent with the manifestation of viral pneumonia (judged by the investigator)
  • Participants who voluntarily sign .

Exclusion criteria

Exclusion Criteria:

  • Participants who cannot take orally, or are suspected to be allergic to Jaktinib hydrochloride, similar drugs or their , or have severe gastrointestinal dysfunction that affects drug absorption;
  • Critical pneumonia patients with other organ failure requiring ICU monitoring and treatment;
  • Participants who have received the following treatments within the specified time window before randomization:

    1. participants have received Janus kinase (JAK) inhibitor, interleukin 6 (IL-6) inhibitor, IL-1 inhibitor, tumor necrosis factor (TNF) inhibitor, T cell or B cell depletion agent, interferon and other drugs within the first two weeks of randomization, except ;
    2. Systematically used CYP 3A4 potent inhibitor or potent inducer in the first five drug half lives at random;
  • Immune deficiency;
  • Participants who have received novel coronavirus vaccine within 1 week before randomization;
  • Prior to randomization, there were the following active and uncontrolled infections: tuberculosis, , syphilis, mycoplasma, chlamydia, parasites, and viral infections other than SARS CoV-2 that required systemic anti-infection treatment;
  • Renal diseases requiring dialysis treatment;
  • Pregnant and lactating women;
  • Any other participants that were considered unsuitable by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Jaktinib 100mg BID

    Jaktinib hydrochloride tablets, 2 x 50mg dosage, BID

    Drug: Jaktinib hydrochloride tablets

  • Placebo comparator
    Placebo

    2 x Placebo tablets, BID

    Drug: Jaktinib hydrochloride tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of Jaktinib

    The proportion of subjects with disease progression or all-cause mortality;

    Time frame: 14 days after randomization

  2. Efficacy of Jaktinib

    The proportion of subjects with disease progression or all-cause mortality;

    Time frame: 28 days after randomization

  3. Efficacy of Jaktinib

    The proportion of subjects whose (National Institute of Allergy and Infectious Disease Ordinal Scale (NIAID-OS) score improved by ≥ 2 points from the baseline

    Time frame: 28 days after randomization

  4. Efficacy of Jaktinib

    The change value of NIAID-OS score compared with the baseline

    Time frame: 28 days after randomization

  5. Efficacy of Jaktinib

    Time interval from randomization to clinical improvement (defined as NIAID-OS 1-3 points)

    Time frame: up to 28 days after randomization

  6. Time interval from randomization to discharge

    Time frame: up to 28 days after randomization

  7. Efficacy of Jaktinib

    The proportion of subjects receiving mechanical ventilation due to disease progression at 3, 7, 14 days after randomization until end of treatment (EOT)

    Time frame: 28 days after randomization

  8. Efficacy of Jaktinib

    the proportion of subjects whose chest High-Resolution CT (HRCT) showed significant absorption of pulmonary inflammation (definition of significant absorption: the lung inflammatory lesions were reduced by more than 50%) at 7, 14 days after treatment until EOT

    Time frame: 28 days after randomization

Secondary outcomes

  1. Safety of Jaktinib

    Incidence rate of adverse events and serious adverse events

    Time frame: up to 2 months after randomization

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Feb 2025, 10 months later.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's planned 10 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2023
First posted
Jan 17, 2023
StartEst.
Apr 2024
Primary completionEst.
Feb 2025
CompletionEst.
Mar 2025
Last update
Oct 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05686629
Responsible party
Sponsor
First posted
Jan 17, 2023
Start date
Apr 2024 (estimated)
Primary completion
Feb 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
Oct 24, 2023

Study contacts

Zhu Luo
Contact
luozhu720@163.com
+86 18980606557
Weimin Li, Prof.
principal investigator · West China Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion